Altre lingue Jiangsu Recbio Technology Co., Ltd.

Azioni

2179

CNE1000057K9

Prezzo di chiusura Hong Kong S.E. Altri mercati azionari 00:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
9,13 ^CNY	0,00%		-1,72%	-15,93%

27/03	Jiangsu Recbio Technology Co., Ltd. e Shanghai Rongsheng Biotech Co.,Ltd. firmano un accordo di cooperazione strategica sul progetto del nuovo vaccino adiuvante	CI
21/03	La perdita di Jiangsu Recbio Technology si riduce nel 2023	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project	27/03
Jiangsu Recbio Technology's Loss Narrows in 2023	21/03
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines	29/12
Jiangsu Recbio Technology Co., Ltd. Announces Positive Results in the Interim Analysis of the Clinical Trial of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in the Philippines	29/12
Jiangsu Recbio Logs Positive Results from Philippines Trial Of Shingles Vaccine	29/12
Jiangsu Recbio Technology to Extend Validity Period of Share Sale	28/12
Jiangsu Recbio Technology Co., Ltd.(SEHK:2179) added to S&P Global BMI Index	18/09/23
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23
China Approves Recbio's Clinical Trial Application for Shingles Vaccine	27/07/23
Jiangsu Recbio Technology Co., Ltd. Announces Acceptance of Clinical Trial Application for the Novel Adjuvanted Recombinant Shingles Vaccine REC610 in China and Overseas Clinical Trial Progress	26/07/23
Jiangsu Recbio Technology Co., Ltd. - Inclusion of Recbio in the MSCI China Small Cap Index	18/05/23
Jiangsu Recbio Technology Selected for Morgan Stanley Capital International China Small Cap Index	17/05/23
Jiangsu Recbio Technology Co., Ltd. Announces Directorate Appointments	11/05/23
Chinese Securities Regulator Approves Jiangsu Recbio Technology's Share Issuance; Stock Sinks 3%	20/04/23
Pfizer signs strategic cooperation pact with China's Sinopharm	13/04/23
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Feng Tao as Non-Executive Director and A Member of the Nomination Committee	03/04/23
Certain H Shares of Jiangsu Recbio Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	30/03/23
Mongolia Grants Emergency Approval for Jiangsu Recbio's Recombinant COVID-19 Vaccine	21/03/23
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Jiangsu Recbio Technology Co., Ltd.

Azioni

2179

CNE1000057K9

Altre lingue

Filtri